Latest News

Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference

26 January 2022

NEW YORK – 26 January 2022 – Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer (NSCLC) and transformational drug delivery technologies to enable alternative routes...

Read more

Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 Million

24 January 2022

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Board of Directors has today authorized the Company’s management to implement a stock repurchase program for up to $5 million of the Company’s common shares at any time. The...

Read more

Tiziana Life Sciences Announces Death of Director

13 January 2022

Tiziana Life Sciences today announced that Dr. Thomas Adams passed away on January 9, 2022. He served as a member of Tiziana Life Science’s Board of Directors since February 2021.

Read more

Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis

10 January 2022

  • - Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response

  • - FDA allows...

Read more

Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference

06 January 2022

NEW YORK, January 6, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that senior management will present at the Biotech Showcase Conference and be available for...

Read more

Information For Shareholders Regarding Migration of UK Shares

23 December 2021

London, 23 December 2021 - Tiziana Life Sciences(Nasdaq: TLSA) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases has added some additional information on its website for shareholders regarding the migration of its UK shares.


Read more

Page 3 of 34 Previous Next